Sep 2026· Medical Oncology· Vol 43· 0 citations· 62 references
Medicine
TL;DR
The rapid evolution of KRAS-targeted therapeutic agents represents a shift from allele-specific inhibition towards a strategy that is mutation/context-dependent, thereby creating further clinical translation opportunities and increased patient benefit.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy in which activating KRAS mutations, present in more than 90% of tumors, constitute the principal oncogenic driver. Advances in structural biology have enabled the pharmacologic targeting of KRAS, a protein historically regarded as 'undrugg...
Joanna Kreidi, C. Hoyek, C. Eslinger et al.· Expert Opinion on Biological...· 0 citations
KRAS mutations are the most common oncogenic driver alterations in non-small cell lung cancer (NSCLC) and define biologically heterogeneous diseases shaped by mutation subtype, co-mutation patterns, and immune contexture. Recent advances in structural and chemical biology have transformed KRAS from an undruggable targe...
E. Garbo, P. Scaparone, Hui Jing Hoe et al.· The Journal of the National...· 0 citations
The development of MRTX1133, zoldonrasib, zoldonrasib (RMC-9805), VS-7375, RMC-5127, and daraxonrasib (RMC-6236) demonstrates that direct targeting of previously undruggable KRAS alleles is becoming clinically feasible, and anti-EGFR combination strategies particularly important in CRC.
T. Sagawa, Masahiro Hirakawa, H. Nagashima et al.· Journal of Gastrointestinal...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) continues to carry a poor prognosis, and only incremental gains in systemic therapy have been made over the past decade. Because activating KRAS mutations are present in more than 90% of PDAC and serve as the inciting oncogenic driver, RAS has long been a coveted but elusive ther...
Y. L. Wu, B. Herzberg, G. Manji· The Oncologist· 0 citations
This review summarizes recent progress in KRAS G12D-targeted inhibitors and degraders, highlighting current challenges and future opportunities for improving KRAS-directed cancer treatment.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a five-year survival rate below 10%. Due to aggressiveness and lack of early detection methods, patients are often diagnosed at an advanced stage, leaving few therapeutic options. This emphasizes the need for a deeper understanding of the mo...
Paul G. Winckler, Georg Vladimirov, Lennart Herrlich et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
